Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways.

Data supports potential for soquelitinib to rebalance the immune system and produce drug-free remissions following discontinuation of therapy

Immunologic markers consistent with soquelitinib’s novel mechanism of action and clinical results

SID data included in late-breaking oral presentation; company to review data at investor and analyst

Excerpt from the Press Release:

SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today the presentation of final data from its randomized, blinded, placebo-controlled Phase 1 trial evaluating soquelitinib in patients with moderate-to-severe atopic dermatitis in two oral sessions at the Society for Investigative Dermatology (SID) Annual Meeting, which is taking place May 13-16, 2026 in Chicago. The first oral presentation covers soquelitinib’s immunologic and clinical activity, and the second late-breaking oral presentation covers its potential to provide prolonged drug-free remissions.

“While there are a number of approved systemic options for atopic dermatitis, they don’t work for all patients and they are limited by the need for prolonged dosing regimens, rapid disease rebound following cessation of therapy, or inconvenient drug administration and monitoring,” said Albert S. Chiou, M.D., MBA, Clinical Professor, Dermatology and Director of Clinical Research in the Department of Dermatology at Stanford University Medical Center. “There is a need for a safe oral systemic therapy that can address these limitations and be effective across the disease spectrum including relapsed/refractory patients. The results of this trial are exciting as they suggest that soquelitinib may meet this need, with the possibility of offering shorter treatment regimens and prolonged disease clearance for patients.”

The trial enrolled 72 patients with moderate-to-severe atopic dermatitis that previously failed one prior topical or systemic therapy. Thirty-five percent of the patients had received a prior systemic therapy.

Click the button below to read the entire Press Release:

Continue Reading The Press Release